These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

883 related items for PubMed ID: 11397887

  • 1. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [Abstract] [Full Text] [Related]

  • 2. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [Abstract] [Full Text] [Related]

  • 5. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 6. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.
    Horm Res; 2004 Sep; 62(5):227-32. PubMed ID: 15477693
    [Abstract] [Full Text] [Related]

  • 7. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 8. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 9. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 10. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
    Jallad RS, Bronstein MD.
    Neuroendocrinology; 2009 Mar; 90(1):82-92. PubMed ID: 19439914
    [Abstract] [Full Text] [Related]

  • 11. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ.
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [Abstract] [Full Text] [Related]

  • 12. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
    Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
    [Abstract] [Full Text] [Related]

  • 13. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR, van den Oever NC, Frölich M, Arias AM, Smit JW, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [Abstract] [Full Text] [Related]

  • 14. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
    Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, SMS995B2401 Study Group.
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
    [Abstract] [Full Text] [Related]

  • 15. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K, Cheer S, Wagstaff AJ.
    Drugs; 2003 Jun; 63(22):2473-99. PubMed ID: 14609359
    [Abstract] [Full Text] [Related]

  • 16. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

  • 17. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen O, Skeie S, Lund-Johansen M, Fougner SL, Bollerslev J, POTA study group.
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
    [Abstract] [Full Text] [Related]

  • 18. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
    Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
    [Abstract] [Full Text] [Related]

  • 19. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J, Rabijewski M, Zgliczyński W.
    Endokrynol Pol; 2005 Jan; 56(6):862-70. PubMed ID: 16821203
    [Abstract] [Full Text] [Related]

  • 20. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U, Quabbe HJ.
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.